Cerevel Therapeutics Holdings, Inc. CERE
Set alert
44.96 +44.96 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 8.19B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -15.40
- Beta
- 1.41
- Short ratio
- 2.37
- Inst. own
- 85.12%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 41.63
- 200-d avg
- 39.55
- 1y target
- 43.40
Analyst view
Consensus: hold
Hold
Price target (mean) 43.40 -3.5% downside
Now 44.96
- Target (low)
- 31.00
- Target (mean)
- 43.40
- Target (high)
- 45.00
Recommendation trend
- 1 month ago 9
- 2 months ago 9
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.80 | -0.80 – -0.80 | -0.63 | -27.0% | 0 | 0.0% | 1 |
| Next quarter | -0.73 | -0.73 – -0.73 | -0.61 | -19.7% | 0 | 0.0% | 1 |
| Current year | -2.83 | -3.25 – -2.41 | -2.67 | -6.0% | 0 | 0.0% | 2 |
| Next year | -2.92 | -3.30 – -2.54 | -2.83 | -3.2% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 27, 2023 | Piper Sandler | Initiated | — | Overweight |
| Aug 6, 2023 | Mizuho | Maintained | Neutral | Neutral |
| Aug 2, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 2, 2023 | B of A Securities | Downgrade | Buy | Neutral |
| Aug 2, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 22, 2023 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 7, 2023 | Mizuho | Maintained | — | Neutral |
| May 3, 2023 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Apr 9, 2023 | TD Cowen | Initiated | — | Outperform |
| Apr 2, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 16, 2023 | JP Morgan | Downgrade | Overweight | Neutral |
| Mar 8, 2023 | Mizuho | Maintained | — | Neutral |
| Feb 22, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Feb 22, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 22, 2023 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Feb 21, 2023 | Goldman Sachs | Maintained | Neutral | Neutral |
| Dec 5, 2022 | JP Morgan | Maintained | — | Overweight |
| Nov 9, 2022 | Mizuho | Maintained | — | Neutral |
| Nov 8, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 31, 2022 | Loop Capital | Initiated | — | Buy |
| Oct 19, 2022 | B of A Securities | Initiated | — | Buy |
| Sep 28, 2022 | Cantor Fitzgerald | Initiated | — | Overweight |
| Sep 25, 2022 | Wells Fargo | Initiated | — | Overweight |
| Sep 20, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Sep 12, 2022 | Evercore ISI Group | Initiated | — | Outperform |
| Aug 22, 2022 | Mizuho | Maintained | — | Neutral |
| Aug 21, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Aug 8, 2022 | Stifel | Maintained | — | Buy |
| Aug 2, 2022 | Mizuho | Maintained | — | Neutral |
| Jul 6, 2022 | Mizuho | Initiated | — | Neutral |